Perspective Therapeutics, Inc. (NYSE:CATX) Shares Acquired by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. raised its stake in Perspective Therapeutics, Inc. (NYSE:CATX - Free Report) by 221.7% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 433,522 shares of the company's stock after purchasing an additional 298,778 shares during the period. Charles Schwab Investment Management Inc. owned 0.64% of Perspective Therapeutics worth $5,788,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also modified their holdings of the company. nVerses Capital LLC purchased a new stake in Perspective Therapeutics in the third quarter valued at about $57,000. US Bancorp DE raised its position in shares of Perspective Therapeutics by 142.7% in the 3rd quarter. US Bancorp DE now owns 6,576 shares of the company's stock valued at $88,000 after purchasing an additional 3,866 shares during the last quarter. Victory Capital Management Inc. acquired a new stake in Perspective Therapeutics in the 2nd quarter worth approximately $117,000. Point72 DIFC Ltd purchased a new stake in Perspective Therapeutics during the 2nd quarter worth approximately $118,000. Finally, Intech Investment Management LLC purchased a new stake in Perspective Therapeutics during the 3rd quarter worth approximately $137,000. 54.66% of the stock is owned by hedge funds and other institutional investors.

Perspective Therapeutics Trading Down 1.7 %

Shares of NYSE:CATX traded down $0.06 during midday trading on Friday, reaching $3.41. 629,897 shares of the company's stock traded hands, compared to its average volume of 861,881. The company has a fifty day simple moving average of $8.99 and a two-hundred day simple moving average of $11.59. Perspective Therapeutics, Inc. has a 1 year low of $2.50 and a 1 year high of $19.05.

Perspective Therapeutics (NYSE:CATX - Get Free Report) last announced its earnings results on Tuesday, November 12th. The company reported ($0.21) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.21). Perspective Therapeutics had a negative net margin of 4,096.66% and a negative return on equity of 27.40%. The business had revenue of $0.37 million for the quarter. On average, equities research analysts forecast that Perspective Therapeutics, Inc. will post -0.88 earnings per share for the current fiscal year.

Analysts Set New Price Targets

CATX has been the subject of a number of research reports. Truist Financial assumed coverage on Perspective Therapeutics in a report on Wednesday, September 25th. They set a "buy" rating and a $21.00 target price for the company. Royal Bank of Canada dropped their price objective on shares of Perspective Therapeutics from $25.00 to $16.00 and set an "outperform" rating on the stock in a report on Monday, November 25th. UBS Group assumed coverage on shares of Perspective Therapeutics in a report on Thursday, October 24th. They set a "buy" rating and a $20.00 target price for the company. Bank of America lowered shares of Perspective Therapeutics from a "buy" rating to a "neutral" rating and lowered their price target for the company from $24.00 to $5.00 in a report on Monday, November 25th. Finally, Oppenheimer cut their price target on Perspective Therapeutics from $22.00 to $16.00 and set an "outperform" rating on the stock in a research report on Friday, November 22nd. One analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company's stock. Based on data from MarketBeat, Perspective Therapeutics presently has a consensus rating of "Moderate Buy" and a consensus target price of $15.14.

Insider Buying and Selling at Perspective Therapeutics

In related news, CEO Johan M. Spoor purchased 14,500 shares of the business's stock in a transaction that occurred on Monday, November 25th. The stock was purchased at an average price of $3.78 per share, with a total value of $54,810.00. Following the completion of the acquisition, the chief executive officer now owns 152,072 shares in the company, valued at $574,832.16. This trade represents a 10.54 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Heidi Henson acquired 25,975 shares of the stock in a transaction on Wednesday, December 4th. The shares were bought at an average cost of $3.85 per share, for a total transaction of $100,003.75. Following the purchase, the director now directly owns 25,975 shares of the company's stock, valued at $100,003.75. The trade was a ∞ increase in their position. The disclosure for this purchase can be found here. In the last 90 days, insiders have bought 67,570 shares of company stock worth $256,789. Corporate insiders own 3.52% of the company's stock.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.